Stock Splits
By The Online Investor Staff, updated Tue., Sep. 17, 8:28 AM
| This Slide: #7 of 25 |
Slide #7. Pluristem Therapeutics Inc. (NASDAQ:PSTI) — 1 for 10 Reverse Split
Announced:
7/24/2019
Stock Split:
1 for 10
Record Date:
7/24/2019
Pay Date:
7/25/2019
PSTI Optionable?:
Yes
Pluristem Therapeutics is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Co.'s product candidates include: PLX-PAD, which is in a multinational clinical trial in critical limb ischemia, and in a multinational clinical trial in recovery following surgery for hip fracture; PLX-R18, which is under development in the United States for acute radiation syndrome, as well as in a trial in the United States and Israel for incomplete hematopoietic recovery following hematopoietic cell transplantation; and PLX-Immune, which is under pre-clinical development for treatment of certain types of human cancer. 
PSTI Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the PSTI Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 84th percentile
(ranked higher than approx. 84% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
